Saturday, April 02, 2011 8:10:31 AM
You know that and we might know that but the investment world does not know that.
Why didn't the company make a strategic decision to have the Cides tested in a Chimp or overseas for humanitaruan use,... long ago?
Even now they can do it if they wanted to. I would say a humanitarian use project somewhere in the world would do more for the technoolgy's advancement than anything done to date by the company during the last 3 years.
The company is strong on science, strong on producing test results, srtong on fine tuning the cides,..etc.
The weakness is in advancing the technology towards a final product. Granted there is huge opposition to such a new technology. But there are countries where because of the human suffering, they could care less for those things. If a solution presents itself, they go for it.
If Eva or someone in Africa (where we are supposed to have some connections) were to help us set up some humanitarian tests and IF they were successful, the stock would propel to the $10 area easliy The company would need to get the proper PR people on board to insure the word gets out,.. that other countries fighting similar diseases hear about it.
The company could then issue a ton load of shares at these higher prices and we would be hme free to moving this technology to a final product.
We could then approah all the other countries that are in need and afterwards the USA would be knocking at OUR door when they see thoses smaller countries having solved HIV, Dengue, Flu, Pink-Eye, etc.
We would probably be able to set up big pharma deals very easliy along the way.
Yes I know you have all sorts of reasons why the company has not or will not do this.
But we are still a couple of years away from doing a clinical trial here. I have been here for over six years and if I would have said to you six years ago, that in six years there will STILL be no clinical trials done and that not even for another year or two,..so 7-8 years before clinical trial since we discovered NNVC.
Yet we had working drugs (on mice) YEARS ago. What about all the lives they could have saved around the world if they would have gone the humanitarian route?
Why not go both routes,... one might enhance the other.
Why didn't the company make a strategic decision to have the Cides tested in a Chimp or overseas for humanitaruan use,... long ago?
Even now they can do it if they wanted to. I would say a humanitarian use project somewhere in the world would do more for the technoolgy's advancement than anything done to date by the company during the last 3 years.
The company is strong on science, strong on producing test results, srtong on fine tuning the cides,..etc.
The weakness is in advancing the technology towards a final product. Granted there is huge opposition to such a new technology. But there are countries where because of the human suffering, they could care less for those things. If a solution presents itself, they go for it.
If Eva or someone in Africa (where we are supposed to have some connections) were to help us set up some humanitarian tests and IF they were successful, the stock would propel to the $10 area easliy The company would need to get the proper PR people on board to insure the word gets out,.. that other countries fighting similar diseases hear about it.
The company could then issue a ton load of shares at these higher prices and we would be hme free to moving this technology to a final product.
We could then approah all the other countries that are in need and afterwards the USA would be knocking at OUR door when they see thoses smaller countries having solved HIV, Dengue, Flu, Pink-Eye, etc.
We would probably be able to set up big pharma deals very easliy along the way.
Yes I know you have all sorts of reasons why the company has not or will not do this.
But we are still a couple of years away from doing a clinical trial here. I have been here for over six years and if I would have said to you six years ago, that in six years there will STILL be no clinical trials done and that not even for another year or two,..so 7-8 years before clinical trial since we discovered NNVC.
Yet we had working drugs (on mice) YEARS ago. What about all the lives they could have saved around the world if they would have gone the humanitarian route?
Why not go both routes,... one might enhance the other.
Recent NNVC News
- In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides • ACCESS Newswire • 05/26/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2026 10:01:46 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2026 08:30:33 PM
- NanoViricides Announces Closing of ~$2 Million Registered Direct Offering • ACCESS Newswire • 05/19/2026 03:55:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/18/2026 12:45:22 PM
- Ebola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricides • ACCESS Newswire • 05/18/2026 12:30:00 PM
- NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering • ACCESS Newswire • 05/15/2026 12:35:00 PM
- NanoViricides, Inc. Has Filed its Quarterly Report - NV-387 Advancing for Phase II • ACCESS Newswire • 05/15/2026 12:00:00 PM
- Recent Hantavirus On A Cruise Ship Highlights the Need for Broad-Spectrum Antiviral Drugs Such as NV-387, Says NanoViricides • ACCESS Newswire • 05/11/2026 12:30:00 PM
- NanoViricides, Inc. Announces Participation in the D. Boral Capital Global Conference • Newsfile • 05/06/2026 07:37:00 PM
- NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA • ACCESS Newswire • 05/04/2026 12:30:00 PM
- Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides • ACCESS Newswire • 04/21/2026 12:30:00 PM
- Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides • ACCESS Newswire • 04/07/2026 12:30:00 PM
- Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides • ACCESS Newswire • 04/01/2026 12:30:00 PM
- NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete • ACCESS Newswire • 03/11/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:30:47 PM
- MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/12/2026 01:30:00 PM
- Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/10/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/30/2025 09:30:18 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 12/16/2025 09:30:05 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/15/2025 09:26:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/26/2025 09:30:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:32:10 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 07:54:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 04:29:54 PM
